Kakinuma Yoshihiko, Honma Satoshi, Morimoto Takashi, Maruyama Hidekazu, Yamazaki Akira, Ishimitsu Toshiyuki, Yamaguchi Iwao
Department of Cardiovascular Control, Kochi Medical School, Kochi, Japan.
Angiology. 2005 Sep-Oct;56(5):641-5. doi: 10.1177/000331970505600519.
Endothelin-1 (ET-1) is known to be a principal factor in the pathogenesis of primary pulmonary hypertension (PPH). Recently intravenous administration of epoprosterol improved the survival rate in PPH. However, the effect of epoprosterol on ET-1 remains to be investigated. Therefore, we studied a patient with PPH who was treated with a low dose of epoprosterol and examined the serum concentration of ET-1 during the treatment. Epoprosterol greatly decreased the serum concentration of ET-1 in parallel with improvement of the clinical course, suggesting that ET-1 level may be a marker for treatment of PPH.
内皮素-1（ET-1）是已知的原发性肺动脉高压（PPH）发病机制中的主要因素。最近，静脉注射依前列醇可提高PPH患者的生存率。然而，依前列醇对ET-1的影响仍有待研究。因此，我们研究了一名接受低剂量依前列醇治疗的PPH患者，并在治疗期间检测了ET-1的血清浓度。依前列醇在改善临床病程的同时，显著降低了ET-1的血清浓度，这表明ET-1水平可能是PPH治疗的一个标志物。
